| Chemical & Physical Properties | |
|---|---|
| CAS Number | 1300031-49-5 |
| Catalog No. | 2A-1170725 |
| Chinese Name | 7-(3,5-二甲基异噁唑-4-基)-8-甲氧基-1-((R)-1-(吡啶-2-基)乙基)-1H-咪唑并[4,5-C]喹啉-2(3H)-酮 |
| Synonyms | 4alg; 1GH; cc-415; 3zyu; I-BET151; GSK1210151A |
| Molecular Formula | C23H21N5O3 |
| Molecular Weight | 415.444 |
| Density | 1.3±0.1 g/cm3 |
| Appearance | white to beige |
| Water Solubility | DMSO: soluble20mg/mL, clear |
| Storage Condition | 2-8°C |
| Application | I-BET151 is a BET bromodomain inhibitor with pIC50s of 6.1, 6.3 and 6.6 for BRD4, BRD2 and BRD3, respectively. |
| HTC | 2934999090 |
| PubChem ID | 123047600 |
| SMILES | COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(C(C)c3ccccn3)c12 |
| InChI | InChI=1S/C23H21N5O3/c1-12-21(14(3)31-27-12)16-9-18-15(10-20(16)30-4)22-19(11-25-18)26-23(29)28(22)13(2)17-7-5-6-8-24-17/h5-11,13H,1-4H3,(H,26,29)/t13-/m1/s1 |
| InChI Key | VUVUVNZRUGEAHB-CYBMUJFWSA-N |
| Hazard Symbols | transportation |
| MSDS | msds/170903_2_1300031_49_5.pdf |
| Bioactivity | I-BET151 is a BET bromodomain inhibitor which inhibits BRD4, BRD2, and BRD3 with pIC50 of 6.1, 6.3, and 6.6, respectively. Related Catalog Signaling Pathways >> Epigenetics >> Epigenetic Reader Domain Research Areas >> Cancer Target pIC50: 6.1 (BRD4), 6.3 (BRD2), 6.6 (BRD3)[1] In Vitro I-BET151 (GSK1210151A) causes a significant dose- and time-dependent decrease in the proportion of myeloma cells in S/G2 phase at 24, 48, and 72 hours. The most pronounced effect is observed at 72 hours in all 6 myeloma cell lines, starting at 100 nM. Dual Ki67/propidium iodide staining confirmed that the majority of live cells resided in the G0 phase after treatment with I-BET151 at 1 μM for 72 hours commensurate with a dose- and time-dependent decrease in cell proliferation and abrogation of bromodeoxyuridine incorporation[2]. In Vivo I-BET151 (GSK1210151A) demonstrates low blood clearance in the rat (~20% liver blood flow) and good oral systemic exposure which resulted in good oral bioavailability. High clearance is observed in the dog (~95% liver blood flow). The systemic exposure in the dog is low, resulting in a poor oral bioavailability of 16%. The high blood clearance in dog correlates well with the high intrinsic clearance observed in dog microsomes and hepatocytes, whereas the low intrinsic clearances seen in rat and mouse (mouse IVC 1.6 mL/min/g; CLb 8 mL/min/kg) correlate with lower in vivo blood clearances in these species. Due to the low systemic exposure observed in the dog, I-BET151 is investigated in the mini-pig as a potential second species for toxicological evaluation where it showed low clearance (~32% liver blood flow) and good bioavailability (65%)[1]. In an in vivo model of subcutaneous myeloma, I-BET151 (50 mg/kg)-treated mice has four- to five fold smaller myeloma tumors (P<0.001) and a significantly reduced rate of tumor size doubling than vehicle-treated mice (P<0.001)[2]. Cell Assay For in vitro cell proliferation and apoptosis assays, myeloma cell lines are cultured by using RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, penicillin 500 IU/mL, and streptomycin 500 μg/mL. Cells are placed in 96-well U-bottom plates at final concentration of 0.2×106 cells per milliliter in a humidified incubator with 5% CO2 at 37°C. For stroma vs nonstroma experiments, myeloma cells are placed in flat-bottom 96-well plates with MS5 cells at >90% confluence or in wells without stroma. Compounds (ie, I-BET151, I-BET762, the inactive isomer I-BET768, and JQ1) are serially diluted into media and added to the cultures at the indicated concentrations, starting from a 10-mM DMSO stock solution.Primary myeloma cells are cultured in flat-bottom 96-well plates in the presence of MS5 stroma cells by using complete medium as above, supplemented with interleukin-6 (IL-6) at 5 ng/mL[2]. Animal Admin Mice[2] NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice are used. In total, 5×106 KMS11 myeloma cells are injected subcutaneously into 9- to 12-week-old NSG mice. When tumors are ≥5 mm in maximum diameter, mice are randomized to receive once daily intraperitoneal injection of either I-BET151 30 mg/kg in 0.9% NaCl plus Kleptose hydroxypropyl betadex 10% (w/v) and DMSO 5% (v/v) pH 5.0 or vehicle solution for a maximum of 21 days. References [1]. Seal J, et al. Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett. 2012 Apr 15;22(8):2968-72. [2]. Chaidos A, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014 Jan 30;123(5):697-705. Chemical & Physical Properties Density 1.3±0.1 g/cm3 Molecular Formula C23H21N5O3 Molecular Weight 415.444 Exact Mass 415.164429 PSA 98.83000 LogP 2.28 Appearance of Characters white to beige Index of Refraction 1.651 InChIKey VUVUVNZRUGEAHB-CYBMUJFWSA-N SMILES COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(C(C)c3ccccn3)c12 Storage condition 2-8°C Water Solubility DMSO: soluble20mg/mL, clear |
| Use of | I-BET151 is a BET bromodomain inhibitor which inhibits BRD4, BRD2, and BRD3 with pIC50 of 6.1, 6.3, and 6.6, respectively. Properties Name 7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1R)-1-pyridin-2-ylethyl]-3H-imidazo[4,5-c]quinolin-2-one Synonym More Synonyms I-BET151 Biological Activity Description I-BET151 is a BET bromodomain inhibitor which inhibits BRD4, BRD2, and BRD3 with pIC50 of 6.1, 6.3, and 6.6, respectively. Related Catalog Signaling Pathways >> Epigenetics >> Epigenetic Reader Domain Research Areas >> Cancer pIC50: 6.1 (BRD4), 6.3 (BRD2), 6.6 (BRD3)[1] References [1]. Seal J, et al. Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett. 2012 Apr 15;22(8):2968-72. [2]. Chaidos A, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014 Jan 30;123(5):697-705. Chemical & Physical Properties Molecular Formula C23H21N5O3 Exact Mass 415.164429 PSA 98.83000 Appearance of Characters white to beige Index of Refraction 1.651 InChIKey VUVUVNZRUGEAHB-CYBMUJFWSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Dangerous Regulations for land transport: 2811 International Dangerous Regulations for sea transport: 2811 International Dangerous Regulations for air transport: 2811 14.2 United Nations shipping name European Land Transport Dangerous Regulations: TOXIC SOLID, ORGANIC, N.O.S. (7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1- (2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one) IMDG: TOXIC SOLID, ORGANIC, N.O.S. (7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1- (2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one) International air transport hazard regulations: Toxic solid, organic, n.o.s. (7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2- pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one) 14.3 Transport hazard categories European Land Transport Danger Regulations: 6.1 International Maritime Transport Danger Regulations: 6.1 International Air Transport Danger Regulations: 6.1 14.4 Package group European Land Transport Danger Regulations: III International Maritime Transport Danger Regulations: III International Air Transport Danger Regulations: III 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| JQ-1 acid | 202592-23-2 | 2A-1170720 |
| OTX015 | 202590-98-5 | 2A-1170721 |
| GNE317 | 1394076-92-6 | 2A-1170722 |
| UNC 1999 | 1431612-23-5 | 2A-1170723 |
| GSK 34 | 1346704-33-3 | 2A-1170724 |
| ARV 825 | 1818885-28-7 | 2A-1170726 |
| d-BET 1 | 1799711-21-9 | 2A-1170727 |
| RO0921 | 1446790-62-0 | 2A-1170728 |
| Tinostamustine EDO-SI01 | 1793059-58-1 | 2A-1170729 |
| leniolisib(CDZ 173) | 1354690-24-6 | 2A-1170730 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS